Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

Circulating Tumor Cells (CTC) in Lung Cancer

NCT02630615
Conditions
Lung Neoplasms
Interventions
Blood draw
Other
Lead sponsor
Shadia Jalal
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Interventions
Guadecitabine, Carboplatin
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Indianapolis, Indiana • Muncie, Indiana • Charlottesville, Virginia + 1 more
Conditions
Neoplasm Metastases
Interventions
RAD001 + AMG479
Drug
Lead sponsor
Shadia Jalal
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Esophageal Cancer, Gastric Cancer, Adenocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Completed Phase 2 Interventional Results available

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

NCT02639065
Conditions
Esophageal Cancer
Interventions
Durvalumab
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Ann Arbor, Michigan